Cover Image

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy

Pneumococcal diseases are associated with a significant clinical and economic burden. The 7-valent pneumococcal conjugate vaccine (PCV-7) has been used for the immunization of newborns against invasive pneumococcal diseases (IPD) in Italy while now, the pneumococcal non-typeable Haemophilus influenz...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paolo Castiglia (Author), Lorenzo Pradelli (Author), Stefano Castagna (Author), Veronica Freguglia (Author), Giorgio Palù (Author), Susanna Esposito (Author)
Format:	Book
Published:	Taylor & Francis Group, 2017-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022)

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea
by: Xu-Hao Zhang, et al.
Published: (2018)

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience
by: Tomas Mrkvan, et al.
Published: (2018)

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
by: Youness Lagoubi, et al.
Published: (2022)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018)

Pneumonia hospitalizations and mortality in children 3 - 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
by: Jalo Iliya, et al.
Published: (2023)

Primary vaccination with the 10-valent pneumococcal non-typeable <it>Haemophilus influenzae </it>protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
by: Dicko Alassane, et al.
Published: (2011)

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
by: Alen Marijam, et al.
Published: (2022)

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
by: Shabir A Madhi, et al.
Published: (2017)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
by: Oana Falup-Pecurariu, et al.
Published: (2017)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019)

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

Estimates on state-specific Pneumococcal Conjugate Vaccines (PCV) coverage in the private sector in the year 2012: Evidence from PCV utilization data
by: Habib Hasan Farooqui, et al.
Published: (2016)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018)

Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries
by: Preetika Banerjee, et al.
Published: (2023)

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
by: Josiah Ryman, et al.
Published: (2024)

Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020)

Vaccination status (PCV13) of children with pneumococcal meningitis
by: Seidullayeva, Aliya, et al.
Published: (2020)

Tingkat Pengetahuan Orang Tua terhadap Penyakit Pneumonia dan Imunisasi Pneumococcal Conjugate Vaccine (PCV) di Indonesia
by: Erlika Saputri, et al.
Published: (2020)

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
by: R. Rupp, et al.
Published: (2019)

Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014
by: Michal Chowers, et al.
Published: (2017)

A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016)
by: Marta Moreira, et al.
Published: (2017)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
by: Goran Bencina, et al.
Published: (2022)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018
by: Larisa Savrasova, et al.
Published: (2021)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019
by: Eiman Mokaddas, et al.
Published: (2021)

Spatial variation and predictors of incomplete pneumococcal conjugate vaccine (PCV) uptake among children aged 12-35 months in Ethiopia: spatial and multilevel analyses
by: Aklilu Habte Hailegebireal, et al.
Published: (2024)

Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7)
by: Javier Nieto Guevara, et al.
Published: (2013)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023)

Impact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?
by: Daniel Jarovsky, et al.
Published: (2023)

Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen
by: Josiah Ryman, et al.
Published: (2024)

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children
by: Catarina Silva-Costa, et al.
Published: (2023)

The Prediction of Surgery Outcomes in Abdominal Tumor Patients with Sepsis by Pcv-aCO2/Ca-cvO2
by: Lyu Y, et al.
Published: (2022)

Indirect effect and pneumococcal conjugate vaccines
by: L. Temimi
Published: (2009)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Indirect effect and pneumococcal conjugate vaccines
by: L. Temimi
Published: (2009)